Bayer/Algeta’s Xofigo Brings New Mechanism To Prostate Cancer Field
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved the first alpha particle-emitting radioactive therapeutic agent, Bayer/Algeta’s Xofigo (radium Ra 223 dichloride), for prostate cancer patients with symptomatic bone metastases, three months ahead of the expected PDUFA date.
You may also be interested in...
Bayer Execs Silent On Plans To Divest Material Sciences
The diversified German big pharma highlighted the sales growth of its five recently launched drugs in the first quarter, but declined to fuel M&A speculation surrounding its non-life sciences division.
Bayer Execs Silent On Plans To Divest Material Sciences
The diversified German big pharma highlighted the sales growth of its five recently launched drugs in the first quarter, but declined to fuel M&A speculation surrounding its non-life sciences division.
Singapore First In Asia To Offer Bayer’s Novel Radiation Therapy For Advanced Prostate Cancer With Bone Metastases
Bayer has launched Xofigo (Ra 223) in Singapore, making it the first Asian nation to offer the treatment and cementing the wealthy city state’s claims as a cutting edge cancer treatment hub.